US FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy

The trial is evaluating the safety and efficacy of Lynparza tablets in germline BRCAm high-risk HER2-negative early breast cancer patients. Credit: Ewa Krawczyk, National Cancer Institute Georgetown Lombardi Comprehensive Cancer Center, National Institutes of Health / Flickr.